CV Therapeutics calls $79.65 million 4.75% convertibles

By Jennifer Chiou

New York, July 13 - CV Therapeutics, Inc. said it will redeem on Aug. 3 all its outstanding $79.645 million 4.75% convertible subordinated notes due March 7, 2007.

The company will pay 101.357% of the principal amount of the notes plus accrued interest up to but not including the redemption date.

CV Therapeutics had said it would use a portion of the proceeds of a 6 million share stock issue and $100 million convertible senior subordinated notes issue for repurchase.

The Palo Alto, Calif., biopharmaceutical company, which focuses on cardiovascular diseases, said Wells Fargo, NA will mail notices of redemption to noteholders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.